Among patients with a BRAF-altered non-CRC GI malignancy, the prevalence of copy number amplification (3.1% vs. 0.3%, p < 0.001) and fusions (12% vs. 2.2%, p < 0.001) were higher when compared to those with CRC (Figure 1, Supplemental Table S2). This evidence concerns the gene BRAF and colorectal carcinoma.